Related Experiment Video

Updated: May 12, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Regulation of tumor angiogenesis by the microtubule-binding protein CLIP-170

Xiaodong Sun1, Fang Li, Bin Dong

  • 1Department of Genetics and Cell Biology, College of Life Sciences, Nankai University, Tianjin 300071, China.

Protein & Cell
|April 4, 2013
PubMed

Insights

Cytoplasmic linker protein 170 (CLIP-170) is highly expressed in breast tumors and drives angiogenesis. Inhibiting CLIP-170 reduces tumor vascularization and growth, identifying it as a potential antiangiogenic target.

Area of Science:

  • Oncology
  • Cell Biology
  • Vascular Biology

Background:

  • Angiogenesis is crucial for tumor growth and metastasis.
  • Current antiangiogenic therapies show promise but require novel targets.
  • Tumor vascularization is a key factor in cancer progression.

Purpose of the Study:

  • To investigate the role of CLIP-170 in tumor angiogenesis.
  • To determine if CLIP-170 is a viable antiangiogenic target.
  • To elucidate the mechanism by which CLIP-170 influences endothelial cells.

Main Methods:

  • Quantitative analysis of CLIP-170 expression in breast tumor samples.
  • In vitro assays for endothelial cell tube formation and sprouting.
  • In vivo studies using mouse models of breast cancer.
  • Assessment of endothelial cell migration, proliferation, and polarization.

Main Results:

  • CLIP-170 is highly expressed in breast tumors and correlates with blood vessel density.
  • CLIP-170 depletion impairs endothelial cell tube formation and sprouting in vitro.
  • Inhibition of CLIP-170 reduces tumor growth and vascularization in mice.
  • CLIP-170 is essential for endothelial cell migration and polarization, but not proliferation.

Conclusions:

  • CLIP-170 plays a critical role in tumor angiogenesis.
  • CLIP-170 is a potential novel therapeutic target for antiangiogenic therapy.
  • Targeting CLIP-170 may inhibit breast tumor growth by reducing vascularization.

More Related Videos

High-resolution Time-lapse Imaging and Automated Analysis of Microtubule Dynamics in Living Human Umbilical Vein Endothelial Cells10:25

High-resolution Time-lapse Imaging and Automated Analysis of Microtubule Dynamics in Living Human Umbilical Vein Endothelial Cells

Published on: August 13, 2016

Strategic Endothelial Cell Tube Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular Matrix08:46

Strategic Endothelial Cell Tube Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular Matrix

Published on: August 14, 2016

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...